Mark L. Faupel, who became SpectRx Inc.'s chief operating officer in January, has been promoted to CEO. He succeeds Mark A. Samuels. Faupel has more than 20 years of experience as a senior executive developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Prior to joining SpectRx in 1998 as vice president of business development and then co-founding Guided Therapeutics, Faupel was a senior executive and co-founder of Biofield Corp.
